These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 14978453)
41. Olanzapine: an updated review of its use in the management of schizophrenia. Bhana N; Foster RH; Olney R; Plosker GL Drugs; 2001; 61(1):111-61. PubMed ID: 11217867 [TBL] [Abstract][Full Text] [Related]
42. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder. Houthoofd SA; Morrens M; Sabbe BG Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365 [TBL] [Abstract][Full Text] [Related]
43. The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. Velligan DI; Prihoda TJ; Sui D; Ritch JL; Maples N; Miller AL J Clin Psychiatry; 2003 May; 64(5):524-31. PubMed ID: 12755654 [TBL] [Abstract][Full Text] [Related]
44. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M J Clin Psychiatry; 2004 Apr; 65(4):551-6. PubMed ID: 15119920 [TBL] [Abstract][Full Text] [Related]
45. Predictors of subjective and objective quality of life in outpatients with schizophrenia. Yamauchi K; Aki H; Tomotake M; Iga J; Numata S; Motoki I; Izaki Y; Tayoshi S; Kinouchi S; Sumitani S; Tayoshi S; Takikawa Y; Kaneda Y; Taniguchi T; Ishimoto Y; Ueno S; Ohmori T Psychiatry Clin Neurosci; 2008 Aug; 62(4):404-11. PubMed ID: 18778437 [TBL] [Abstract][Full Text] [Related]
46. Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment. Velligan DI; Miller AL J Clin Psychiatry; 1999; 60 Suppl 23():25-8. PubMed ID: 10625197 [TBL] [Abstract][Full Text] [Related]
47. Determinants of work outcome in neuroleptic-resistant schizophrenia and schizoaffective disorder: cognitive impairment and clozapine treatment. Kaneda Y; Jayathilak K; Meltzer H Psychiatry Res; 2010 Jun; 178(1):57-62. PubMed ID: 20452677 [TBL] [Abstract][Full Text] [Related]
48. [Use of atypical antipsychotics in Charles Perrens psychiatric hospital (Bordeaux) analysis of prescribing practices for Amisulpride, Clozapine, Olanzapine and Risperidone]. Bret P; Bonnet F; Bret MC; Jaffré A Encephale; 2002; 28(4):329-42. PubMed ID: 12232542 [TBL] [Abstract][Full Text] [Related]
49. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO]. István S; Agoston T; Tamás T; Zoltán J Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029 [TBL] [Abstract][Full Text] [Related]
57. New antipsychotics and schizophrenia: a review on efficacy and side effects. Serretti A; De Ronchi D; Lorenzi C; Berardi D Curr Med Chem; 2004 Feb; 11(3):343-58. PubMed ID: 14965236 [TBL] [Abstract][Full Text] [Related]
58. Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. Krakowski MI; Czobor P; Nolan KA J Clin Psychopharmacol; 2008 Oct; 28(5):485-93. PubMed ID: 18794642 [TBL] [Abstract][Full Text] [Related]